Microneedling does not prevent future hair transplants, but some surgeons report the skin becomes "harder" in treated areas. There is no clear evidence to confirm this effect.
The user is seeking advice on effectively applying a liposomal solution of Minoxidil and Finasteride for hair loss, specifically targeting the roots without wasting the product. They find it challenging to use only 1 ml to cover thinning areas on the front and crown.
The user saw significant hair regrowth using topical minoxidil and finasteride, even on areas not directly treated. They used local Algerian products with 5% minoxidil and 0.1% finasteride and reported no side effects.
The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
The user is seeking advice on treating male pattern baldness (MPB) while dealing with seborrheic dermatitis, specifically asking about the use of finasteride (Fin) and minoxidil (Min). They are concerned about side effects and are looking for recommendations to improve overall hair thickness, especially on the crown.
Body hair is more resilient than scalp hair due to different gene expressions and DHT sensitivity. Treatments like minoxidil and finasteride are used for hair loss, but they have varying effects on body and scalp hair.
Topical finasteride as a potential alternative to oral finasteride for reducing DHT levels on the scalp with fewer side effects, and other hair loss treatments such as minoxidil.
The user switched from liquid to foam minoxidil to reduce skin irritation but finds foam harder to apply effectively to the scalp. A suggestion was made to melt the foam into a liquid for easier application.
A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
A 27-year-old male experienced hair loss and dermatitis, which improved with tea tree oil and neem extract. He is considering using a 2% Ketoconazole solution for further treatment.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.
Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.
Using a dermaroller can enhance hair regrowth, especially when combined with minoxidil, and is recommended at depths of 0.75-1.5mm weekly. Microneedling boosts absorption and blood flow, and red light therapy is also being considered for hair growth.
User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.
BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.
A 22-year-old male using 0.5mg Dutasteride and 2.5mg oral Minoxidil daily for 5.5 months reports increased shedding and scalp itching. He also experienced acne and is concerned about whether the shedding is normal and if daily hair washing for seborrheic dermatitis is causing dryness.
The conversation discusses a new 0.3% tretinoin topical launched by MinoxidilMax for mixing with other solutions, with some users expressing concern about potential skin irritation compared to lower concentrations. MinoxidilMax has also released other products like topical Dutasteride and RU58841.
The user is experiencing hair loss despite using dutasteride, minoxidil, and ketoconazole shampoo, and is concerned about continued shedding. Suggestions include checking for nutrient deficiencies, consulting a dermatologist, and considering other potential causes like seborrheic dermatitis or telogen effluvium.
The user experienced significant hair loss on the scalp, eyebrows, eyelashes, and pubic area, along with itchy, flaky skin and red patches. They have a history of eczema and dermatitis and suspect that stopping shampoo use and taking Ritalin may have contributed to the issue.
The conversation discusses using microneedling with growth factor serum, PRF injections, dutasteride, oral and topical minoxidil, and topical exosomes to treat hair loss, particularly on the crown. OP plans to microneedle twice a month and seeks feedback on Korean growth factor serums.
The conversation is about the potential format of Breezula, a hair loss treatment, and concerns that it might be greasy or sticky. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.
The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.
Topical finasteride can reduce scalp DHT as effectively as oral finasteride with fewer systemic effects, but availability is limited. Some users make their own solutions due to limited access.
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.